Alpha Teknova (NASDAQ:TKNO – Get Free Report) and Charles River Laboratories International (NYSE:CRL – Get Free Report) are both healthcare companies, but which is the better investment? We will compare the two businesses based on the strength of their valuation, risk, earnings, profitability, analyst recommendations, institutional ownership and dividends.
Volatility & Risk
Alpha Teknova has a beta of 0.64, indicating that its stock price is 36% less volatile than the S&P 500. Comparatively, Charles River Laboratories International has a beta of 1.38, indicating that its stock price is 38% more volatile than the S&P 500.
Valuation & Earnings
This table compares Alpha Teknova and Charles River Laboratories International”s top-line revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Alpha Teknova | $40.52 million | 9.71 | -$17.26 million | ($0.31) | -23.68 |
| Charles River Laboratories International | $4.02 billion | 3.55 | -$144.34 million | ($4.85) | -61.60 |
Alpha Teknova has higher earnings, but lower revenue than Charles River Laboratories International. Charles River Laboratories International is trading at a lower price-to-earnings ratio than Alpha Teknova, indicating that it is currently the more affordable of the two stocks.
Profitability
This table compares Alpha Teknova and Charles River Laboratories International’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Alpha Teknova | -38.37% | -24.94% | -16.53% |
| Charles River Laboratories International | -5.96% | 15.75% | 6.51% |
Analyst Ratings
This is a breakdown of recent recommendations and price targets for Alpha Teknova and Charles River Laboratories International, as reported by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Alpha Teknova | 1 | 1 | 2 | 0 | 2.25 |
| Charles River Laboratories International | 1 | 3 | 12 | 0 | 2.69 |
Alpha Teknova presently has a consensus price target of $7.50, suggesting a potential upside of 2.18%. Charles River Laboratories International has a consensus price target of $255.65, suggesting a potential downside of 14.43%. Given Alpha Teknova’s higher probable upside, equities analysts plainly believe Alpha Teknova is more favorable than Charles River Laboratories International.
Institutional and Insider Ownership
13.8% of Alpha Teknova shares are owned by institutional investors. Comparatively, 98.9% of Charles River Laboratories International shares are owned by institutional investors. 13.2% of Alpha Teknova shares are owned by insiders. Comparatively, 1.3% of Charles River Laboratories International shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.
Summary
Charles River Laboratories International beats Alpha Teknova on 8 of the 14 factors compared between the two stocks.
About Alpha Teknova
Alpha Teknova, Inc. produces critical reagents for the research, discovery, development, and commercialization of novel therapies, vaccines, and molecular diagnostics in the United States and internationally. The company offers pre-poured media plates for cell growth and cloning; liquid cell culture media and supplements for cellular expansion; and molecular biology reagents for sample manipulation, resuspension, and purification. It provides lab essentials which provides chemical formulations for use in biological research and drug discovery; and clinical solutions, a custom product used in the development and production of protein therapies, gene therapies, mRNA vaccines, and diagnostic kits. The company serves its products to life sciences market, including pharmaceutical and biotechnology companies, contract development and manufacturing organizations, in vitro diagnostic franchises, as well as academic and government research institutions. Alpha Teknova, Inc. was founded in 1996 and is headquartered in Hollister, California.
About Charles River Laboratories International
Charles River Laboratories International, Inc. provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing). The RMS segment produces and sells rodents, and purpose-bred rats and mice for use by researchers. This segment also provides a range of services to assist its clients in supporting the use of research models in research and screening pre-clinical drug candidates, including research models, genetically engineered models and services, insourcing solutions, and research animal diagnostic services. The DSA segment offers early and in vivo discovery services for the identification and validation of novel targets, chemical compounds, and antibodies through delivery of preclinical drug and therapeutic candidates ready for safety assessment; and safety assessment services, such as toxicology, pathology, safety pharmacology, bioanalysis, drug metabolism, and pharmacokinetics services. The Manufacturing segment provides in vitro methods for conventional and rapid quality control testing of sterile and non-sterile pharmaceuticals and consumer products. This segment also offers specialized testing of biologics that are outsourced by pharmaceutical and biotechnology companies. It also provides contract vivarium operation services to biopharmaceutical clients. The company was founded in 1947 and is headquartered in Wilmington, Massachusetts.
Receive News & Ratings for Alpha Teknova Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alpha Teknova and related companies with MarketBeat.com's FREE daily email newsletter.
